Building Your Peripheral Artery Disease Toolkit: Medical Management of Peripheral Artery Disease in 2022

被引:8
作者
Bhagirath, Vinai C. [1 ,2 ]
Nash, David [3 ]
Wan, Darryl [1 ]
Anand, Sonia S. [1 ,2 ]
机构
[1] McMaster Univ, Dept Med, Hamilton, ON, Canada
[2] Populat Hlth Res Inst, Hamilton, ON, Canada
[3] Univ Ottawa, Fac Med, Ottawa, ON, Canada
关键词
HOME-BASED EXERCISE; SMOKING-CESSATION; HIGH-RISK; INTERMITTENT CLAUDICATION; CARDIAC REHABILITATION; CARDIOVASCULAR EVENTS; ANTIPLATELET THERAPY; SUPERVISED EXERCISE; ORAL ANTICOAGULANTS; MEDITERRANEAN DIET;
D O I
10.1016/j.cjca.2022.02.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Peripheral artery disease (PAD) is associated with substantial morbidity, including a high risk of cardiovascular and limb events and death. A growing body of evidence has demonstrated the benefits of antithrombotic therapy, lipid lowering, blood pressure control, diabetes management, smoking cessation, and exercise programs on improving symptoms and reducing these complications. Guidelines make specific recommendations on how to use these strategies to prevent adverse cardiovascular and limb outcomes in patients with PAD. Unfortunately, antithrombotic therapies, statins, optimal antihypertensives, smoking cessation counselling and therapies, and exercise programs have all been consistently shown to be underutilised in PAD patients both in Canada and globally. A variety of barriers to optimal utilisation of evidence-based medical therapies have been described at the patient, health care provider, and system levels. These include lack of knowledge among patients and health care providers, and lack of access to secondary prevention programs. We review the evidence for preventive therapies in PAD, evidence for underutilisation of these therapies, and barriers to their use. Core elements of PAD secondary prevention clinics are proposed, and a summary of optimal medical therapies and relevant tools is provided. This review may help clinicians who treat patients with PAD to develop a toolkit to overcome these barriers in order to improve utilisation of medical therapies, with the ultimate goal of improving outcomes for PAD patients.
引用
收藏
页码:634 / 644
页数:11
相关论文
共 112 条
[1]   Exercise therapy in routine management of peripheral arterial disease and intermittent claudication: a scoping review [J].
Abaraogu, Ukachukwu O. ;
Abaraogu, Onyinyechukwu D. ;
Dall, Philippa M. ;
Tew, Garry ;
Stuart, Wesley ;
Brittenden, Julie ;
Seenan, Chris A. .
THERAPEUTIC ADVANCES IN CARDIOVASCULAR DISEASE, 2020, 14
[2]   2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) [J].
Aboyans, Victor ;
Ricco, Jean-Baptiste ;
Bartelink, Marie-Louise E. L. ;
Bjorck, Martin ;
Brodmann, Marianne ;
Cohnert, Tina ;
Collet, Jean-Philippe ;
Czerny, Martin ;
De Carlo, Marco ;
Debus, Sebastian ;
Espinola-Klein, Christine ;
Kahan, Thomas ;
Kownator, Serge ;
Mazzolai, Lucia ;
Naylor, A. Ross ;
Roffi, Marco ;
Roether, Joachim ;
Sprynger, Muriel ;
Tendera, Michal ;
Tepe, Gunnar ;
Venermo, Maarit ;
Vlachopoulos, Charalambos ;
Desormais, Ileana .
EUROPEAN HEART JOURNAL, 2018, 39 (09) :763-+
[3]  
Abramson BL, 2005, CAN J CARDIOL, V21, P997
[4]   Inclusion of People With Peripheral Artery Disease in Cardiac Rehabilitation Programs: A Pan-Canadian Survey [J].
Ahden, Shobhit ;
Ngo, Vivian ;
Hoskin, Jordan ;
Mach, Vanna ;
Magharious, Selvia ;
Tambar, Amandeep ;
Brooks, Dina ;
Hebert, Andree-Anne ;
Marzolini, Susan .
HEART LUNG AND CIRCULATION, 2021, 30 (07) :1031-1043
[5]  
Anand S, 2007, NEW ENGL J MED, V357, P217
[6]   Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials [J].
Anand, Sonia S. ;
Hiatt, Will ;
Dyal, Leanne ;
Bauersachs, Rupert ;
Berkowitz, Scott D. ;
Branch, Kelley R. H. ;
Debus, Sebastian ;
Fox, Keith A. A. ;
Liang, Yan ;
Muehlhofer, Eva ;
Nehler, Mark ;
Haskell, Lloyd P. ;
Patel, Manesh ;
Szarek, Michael ;
Yusuf, Salim ;
Eikelboom, John ;
Bonaca, Marc P. .
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2022, 29 (05) :E181-E189
[7]   Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial [J].
Anand, Sonia S. ;
Eikelboom, John W. ;
Dyal, Leanne ;
Bosch, Jackie ;
Neumann, Christoph ;
Widimsky, Petr ;
Avezum, Alvaro A. ;
Probstfield, Jeffrey ;
Bruns, Nancy Cook ;
Fox, Keith A. A. ;
Bhatt, Deepak L. ;
Connolly, Stuart J. ;
Yusuf, Salim .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (25) :3271-3280
[8]   Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial [J].
Anand, Sonia S. ;
Bosch, Jackie ;
Eikelboom, John W. ;
Connolly, Stuart J. ;
Diaz, Rafael ;
Widimsky, Peter ;
Aboyans, Victor ;
Alings, Marco ;
Kakkar, Ajay K. ;
Keltai, Katalin ;
Maggioni, Aldo P. ;
Lewis, Basil S. ;
Stoerk, Stefan ;
Zhu, Jun ;
Lopez-Jaramillo, Patricio ;
O'Donnell, Martin ;
Commerford, Patrick J. ;
Vinereanu, Dragos ;
Pogosova, Nana ;
Ryden, Lars ;
Fox, Keith A. A. ;
Bhatt, Deepak L. ;
Misselwitz, Frank ;
Varigos, John D. ;
Vanassche, Thomas ;
Avezum, Alvaro A. ;
Chen, Edmond ;
Branch, Kelley ;
Leong, Darryl P. ;
Bangdiwala, Shrikant I. ;
Hart, Robert G. ;
Yusuf, Salim .
LANCET, 2018, 391 (10117) :219-229
[9]   Oral anticoagulants in patients with coronary artery disease [J].
Anand, SS ;
Yusuf, S .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (04) :62S-69S
[10]  
[Anonymous], OMSC